Have any recent us patents been filed for olaparib?

Has olaparib received any new US patents lately?

Olaparib, marketed as Lynparza, receives ongoing patent protection through formulation, method-of-use, and combination therapy patents rather than core compound patents. Recent filings focus mainly on specific patient populations and drug pairings.

How do new olaparib patents fit into its overall timeline?

Olaparib’s core compound patent expired in the United States in 2023. Core compound protection ended, but secondary patents covering specific uses and formulations extend exclusivity into the generic entry period.

What recent patents cover olaparib use with other drugs?

AstraZeneca has filed US patents for olaparib combined with immune checkpoint inhibitors such as durvalumab and pembrolizumab. These claims cover treatment of ovarian, breast, pancreatic, and prostate cancers in patients with BRCA mutations. Claims also include dosing schedules and patient selection criteria based on homologous recombination repair deficiency.

What patents address olaparib in new patient populations?

Recent filings include patents for olaparib monotherapy in prostate cancer men with DNA repair gene mutations beyond BRCA. The claims specify testing for mutations in genes such as ATM, CHEK2, and PALB2 and using olaparib as first-line treatment in these eroding or metastatic disease settings.

How are companies trying to evergreening olaparib patents?

AstraZeneca and Merck have pursued broad claims around olaparib’s HRD-positive status and patient selection biomarkers. Biomarker-guided patient selection claims help keep control over high-volume clinical areas such as ovarian cancer and breast cancer.

Why are companies challenging these patents?

Generic manufacturers have filed Paragraph IV challenges against several olaparib formulation and method-of-use patents. Paragraph IV notices sent to AstraZeneca indicate attempts to launch generic versions of Lynparza before some secondary patents expire.

Can generics launch before these patents expire?

Generic entry depends on successful challenge of the listed patents or settlement agreements. Many olaparib patents listed in the FDA Orange Book are still active, listed patents prevent immediate generic entry until challenges are resolved or patents expire.

When do the secondary patents expire?

Secondary patents on olaparib are scheduled to expire between 2033 and 2037. Those dates depend on pediatric extensions and terminal disclaimers that AstraZeneca applied to several filings.